273 related articles for article (PubMed ID: 9640486)
1. Mibefradil: a new class of calcium-channel antagonists.
Billups SJ; Carter BL
Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
[TBL] [Abstract][Full Text] [Related]
2. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
Brogden RN; Markham A
Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
[TBL] [Abstract][Full Text] [Related]
3. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
4. Mibefradil: a selective T-type calcium antagonist.
Massie BM
Am J Cardiol; 1997 Nov; 80(9A):23I-32I. PubMed ID: 9375939
[TBL] [Abstract][Full Text] [Related]
5. Differential properties of mibefradil in hypertension and angina.
Kobrin I
J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
[TBL] [Abstract][Full Text] [Related]
6. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
Massie BM
Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
[TBL] [Abstract][Full Text] [Related]
7. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
[TBL] [Abstract][Full Text] [Related]
8. Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
Davies GJ; Tzivoni D; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):34C-39C. PubMed ID: 9286852
[TBL] [Abstract][Full Text] [Related]
9. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
[TBL] [Abstract][Full Text] [Related]
10. Mibefradil--a new calcium-channel blocker.
Med Lett Drugs Ther; 1997 Nov; 39(1013):103-5. PubMed ID: 9391500
[No Abstract] [Full Text] [Related]
11. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
Van Der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
Br J Clin Pharmacol; 1999 May; 47(5):493-8. PubMed ID: 10336572
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
Noll G; Lüscher TF
Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
[TBL] [Abstract][Full Text] [Related]
13. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
Davies GJ; Kobrin I; Caspi A; Reisin LH; de Albuquerque DC; Armagnijan D; Coelho OR; Schneeweiss A
Am Heart J; 1997 Aug; 134(2 Pt 1):220-8. PubMed ID: 9313601
[TBL] [Abstract][Full Text] [Related]
14. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
Schneeweiss A; Kobrin I; Charlon V; Caspi A; Marmor A; Sclarovsky S; Reisin L; Schlesinger Z
Am Heart J; 1998 Feb; 135(2 Pt 1):272-80. PubMed ID: 9489976
[TBL] [Abstract][Full Text] [Related]
15. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
Alpert JS; Kobrin I; DeQuattro V; Friedman R; Shepherd A; Fenster PE; Thadani U
Am J Cardiol; 1997 Apr; 79(8):1025-30. PubMed ID: 9114758
[TBL] [Abstract][Full Text] [Related]
16. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
[TBL] [Abstract][Full Text] [Related]
17. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
Frishman WH; Bittar N; Glasser S; Habib G; Smith W; Pordy R
Clin Cardiol; 1998 Jul; 21(7):483-90. PubMed ID: 9669057
[TBL] [Abstract][Full Text] [Related]
18. Diversity of calcium antagonists.
Pitt B
Clin Ther; 1997; 19 Suppl A():3-17. PubMed ID: 9385501
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist.
Abernethy DR
Am J Cardiol; 1997 Aug; 80(4B):4C-11C. PubMed ID: 9286848
[TBL] [Abstract][Full Text] [Related]
20. Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
Cleophas TJ; van der Sluijs J; van der Vring JA; Daniëls MC; Holwerda KJ; Withagen AJ; Schelling A; Hendriks MG; Zwinderman AH
J Clin Pharmacol; 1999 Jul; 39(7):738-46. PubMed ID: 10392329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
